Panel Endorses New Blood Thinner
An FDA advisory panel has voted unanimously to recommend approval of the investigational anticoagulant dabigatran to reduce the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
The Cardiovascular and Renal Drugs Advisory Committee on Monday voted 9 to 0 that dabigatran works at least as well as the popular blood thinner warfarin. However, because dabigatran doesn't require laboratory monitoring, it doesn't present some of the same issues that make warfarin notoriously difficult to use.
The positive vote was no surprise: FDA reviewers last week released a glowing review of dabigatran, made by Boehringer Ingelheim, and recommended approval of the drug.
National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.